Drug Trial Radar · NCT02347332
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Apr 25, 2014
Primary completion
Oct 20, 2017
Study completion Nov 23, 2018
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For patients relapsing after platinum-based therapy, few data are available. The current use of cetuximab associated with radiotherapy in localized disease and associated with platinum-based chemotherapy in the first-line setting stresses the need for new therapeutic options at later stages of SCCHN.Vinca-alkaloids demonstrated activity in SCCHN. Vinflunine demonstrated superior antitumour activity to vinorelbine in preclinical animal models. Recent preliminary phase I results of the vinflunine plus methotrexate combination in SCCHN, based on a clinical review, show encouraging antitumour activity and an acceptable safety profile. Therefore the combination of vinflunine and methotrexate appears a promising salvage regimen after platinum failure. The present study has been designed as a multicenter, randomised phase III study which will compare the combination of IV vinflunine with methotrexate to methotrexate alone in SCCHN patients having failed platinum-based therapy.
Conditions
- Recurrent or Metastatic Head and Neck Carcinoma
Interventions
VinflunineDrug
MethotrexateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival in the ITT Population (Months)Time frame: Participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut de Recherche Pierre Fabre
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.